Vapreotide acetate salt
Modify Date: 2024-01-02 08:06:47
Vapreotide acetate salt structure
|
Common Name | Vapreotide acetate salt | ||
|---|---|---|---|---|
| CAS Number | 103222-11-3 | Molecular Weight | 1131.371 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 1540.9±65.0 °C at 760 mmHg | |
| Molecular Formula | C57H70N12O9S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 885.7±34.3 °C | |
Use of Vapreotide acetate saltVapreotide is a NK1R antagonist, with an IC50 of 330 nM. Sequence: Phe-Cys-Tyr-Trp-Lys-Val-Cys-Trp-NH2(Disulfide bridge: Cys2-Cys7). |
| Name | rc 160 |
|---|---|
| Synonym | More Synonyms |
| Description | Vapreotide is a NK1R antagonist, with an IC50 of 330 nM. Sequence: Phe-Cys-Tyr-Trp-Lys-Val-Cys-Trp-NH2(Disulfide bridge: Cys2-Cys7). |
|---|---|
| Related Catalog | |
| Target |
330 nM (NK1R)[1]. |
| In Vitro | Vapreotide attenuates the effect of SP on calcium release in a concentration-dependent manner. The concentration required for Vapreotide to completely inhibit the effect of SP is about 100 times higher than that required for the NK1R antagonist aprepitant. The effect of Vapreotide on cell proliferation is mediated primarily by SSTR2. In order to further establish the NK1R antagonist effect of Vapreotide, U373MG cells are pretreated with SSTR2 selective antagonist CYN followed by incubation with Vapreotide and SP stimulation. The results show that pretreatment with CYN does not reverse the inhibitory effect of Vapreotide on SP-stimulated IL-8 mRNA expression. Vapreotide reduces HIV-1 replication in MDM as indicated by limited HIV gag mRNA expression compared to control MDM. In addition, SP treatment (10 μM) reverses Vapreotide inhibition of HIV-1 replication in MDM. This observation indicates that the inhibition of HIV-1 replication by Vapreotide is most likely due to its interaction with NK1R[1]. |
| Cell Assay | The HEK293-NK1R cells and U373MG cells are incubated with or without Vapreotide (0, 5, 10, 20 μM) for 10 minutes and then incubated with or without SP for 3 hours. In some experiments, cells are first incubated with CYN for 10 minutes, and then Vapreotide is added and incubated for an additional 10 minutes, followed by stimulation with SP for 3 hours. Mock treated cells are used as controls[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 1540.9±65.0 °C at 760 mmHg |
| Molecular Formula | C57H70N12O9S2 |
| Molecular Weight | 1131.371 |
| Flash Point | 885.7±34.3 °C |
| Exact Mass | 1130.483032 |
| PSA | 401.24000 |
| LogP | 3.47 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.699 |
| Storage condition | −20°C |
| Safety Phrases | 22-24/25 |
|---|
| D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2 |
| 1H-indole-3-propanamide, α-[[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloeicos-4-yl]carbonyl]amino]-, (αS)- |
| H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 |
| Octastatin |
| (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide |
| Vapreotide Acetate |
| (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxo-2-propanyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide |
| 1H-Indole-3-propanamide, α-[[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12 ,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloeicos-4-yl]carbonyl]amino]-, (αS)- |
| vapreotide |
| FCYWKVCW-NH2 |
| (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide |
| RC-160 |
| D-Phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-tryptophanamide Cyclic (2®7)-Disulfide |
- GL Biochem (Shanghai) Ltd.
- China
- Product Name: Vapreotide
- Price: $Inquiry/1g
- Purity: 98.0%
- Stocking Period: Inquiry
- Contact: Jackie Yang
- DC Chemicals Limited
- China
- Product Name: Vapreotide
- Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
- Purity: 98.0%
- Stocking Period: 3 Day
- Contact: Tony Cao
- Zhejiang Hangyu API Co., Ltd
- China
- Product Name: Vapreotide
- Price: $Inquiry/1kg
- Purity: 99.0%
- Stocking Period: 1 Day
- Contact: Vinnie
Get all suppliers and price by the below link:
Vapreotide acetate salt suppliers
Price: $418/10mM*1mLinWater
Reference only. check more Vapreotide acetate salt price